A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC

NCT06190639 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: sintilimab

Sponsor

Zhejiang Cancer Hospital